Last reviewed 2026-05-25 · How we verify

Neseritide

Mayo Clinic · Phase 1 active Small molecule ✓ Verified May 2026

Neseritide is a Small molecule drug developed by Mayo Clinic. It is currently in Phase 1 development. Also known as: BNP, Nesiritide, BNP.

Neseritide is a medication studied for its potential use in treating Diastolic Heart Failure and Acute Kidney Failure. According to ClinicalTrials.gov, it has been investigated in a study titled "A Study of the Acute Hemodynamic and Myocardial Effects of Nesiritide in Diastolic Heart Failure."

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Neseritide
Also known as	BNP, Nesiritide, BNP
Sponsor	Mayo Clinic
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of Nesiritide in Diastolic Heart Failure. (PHASE1, PHASE2)
BNP (Nesiritide) vs. Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery. (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Neseritide CI brief — competitive landscape report
Neseritide updates RSS · CI watch RSS
Mayo Clinic portfolio CI

Frequently asked questions about Neseritide

What is Neseritide?

Neseritide is a Small molecule drug developed by Mayo Clinic.

Who makes Neseritide?

Neseritide is developed by Mayo Clinic (see full Mayo Clinic pipeline at /company/mayo-clinic).

Is Neseritide also known as anything else?

Neseritide is also known as BNP, Nesiritide, BNP.

What development phase is Neseritide in?

Neseritide is in Phase 1.

Manufacturer: Mayo Clinic — full pipeline
Therapeutic area: All drugs in Other
Also known as: BNP, Nesiritide, BNP

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing